Tharimmune, Inc.
THAR · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.01 | 0.01 | -0.20 |
| FCF Yield | -20.47% | -76.85% | -75.71% | -74.63% |
| EV / EBITDA | -1.94 | -1.06 | -0.12 | 0.23 |
| Quality | ||||
| ROIC | -299.99% | 468.81% | -294.23% | -124.76% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.88 | 0.62 | 1.06 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 57.51% | 11.36% | -5.93% | -31.41% |
| Safety | ||||
| Net Debt / EBITDA | 1.08 | 0.32 | 0.93 | 1.24 |
| Interest Coverage | -300.46 | -300.63 | -5,075.81 | -1,284.67 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |